INPP4A
Basic information
Region (hg38): 2:98444854-98594392
Previous symbols: [ "INPP4" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the INPP4A gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | |||||
missense | 31 | 32 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 1 | |||||
Total | 0 | 2 | 31 | 5 | 7 |
Variants in INPP4A
This is a list of pathogenic ClinVar variants found in the INPP4A region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-98520084-C-T | Dyskeratosis congenita, autosomal dominant 1 | Likely pathogenic (Oct 09, 2017) | ||
2-98520092-G-A | not specified | Uncertain significance (Dec 01, 2022) | ||
2-98520125-C-T | not specified | Uncertain significance (Aug 21, 2024) | ||
2-98520694-A-G | not specified | Uncertain significance (Jan 04, 2022) | ||
2-98520695-C-T | Intellectual disability | Pathogenic (Dec 01, 2019) | ||
2-98533401-C-T | not specified | Uncertain significance (Nov 15, 2024) | ||
2-98533407-A-G | not specified | Uncertain significance (Jun 29, 2023) | ||
2-98533471-G-A | Likely benign (Oct 23, 2018) | |||
2-98535782-T-A | Likely benign (Sep 24, 2018) | |||
2-98535806-ACT-A | Pectus excavatum;Nystagmus;Microcephaly;Hypotonia;visual disturbance | Likely pathogenic (Jun 20, 2019) | ||
2-98535813-G-A | not specified | Uncertain significance (Sep 07, 2022) | ||
2-98535834-T-G | not specified | Uncertain significance (Feb 26, 2024) | ||
2-98537897-G-A | not specified | Uncertain significance (May 23, 2024) | ||
2-98537970-G-A | not specified | Uncertain significance (Dec 07, 2024) | ||
2-98538948-G-A | not specified | Uncertain significance (Aug 14, 2024) | ||
2-98538979-C-T | not specified | Uncertain significance (Oct 12, 2021) | ||
2-98539530-T-C | not specified | Uncertain significance (Nov 17, 2022) | ||
2-98539535-T-C | Benign (Dec 31, 2019) | |||
2-98539536-G-A | not specified | Uncertain significance (Jun 18, 2024) | ||
2-98539636-G-A | not specified | Uncertain significance (Jul 25, 2023) | ||
2-98543878-G-A | not specified | Uncertain significance (May 25, 2022) | ||
2-98543909-C-A | not specified | Uncertain significance (Sep 14, 2022) | ||
2-98543945-C-T | not specified | Uncertain significance (Aug 14, 2023) | ||
2-98543988-C-T | Benign (Dec 31, 2019) | |||
2-98543999-A-G | not specified | Uncertain significance (Jan 02, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
INPP4A | protein_coding | protein_coding | ENST00000074304 | 24 | 149537 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 0.000485 | 124658 | 0 | 9 | 124667 | 0.0000361 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.35 | 357 | 585 | 0.611 | 0.0000368 | 6344 |
Missense in Polyphen | 128 | 267.58 | 0.47836 | 2835 | ||
Synonymous | 0.691 | 224 | 238 | 0.943 | 0.0000162 | 1886 |
Loss of Function | 5.84 | 7 | 52.8 | 0.133 | 0.00000279 | 597 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000170 | 0.000162 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000464 | 0.0000464 |
European (Non-Finnish) | 0.0000273 | 0.0000265 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000333 | 0.0000327 |
Other | 0.000178 | 0.000165 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the hydrolysis of the 4-position phosphate of phosphatidylinositol 3,4-bisphosphate, inositol 1,3,4- trisphosphate and inositol 3,4-bisphosphate.;
- Pathway
- Inositol phosphate metabolism - Homo sapiens (human);Phosphatidylinositol signaling system - Homo sapiens (human);Inositol Phosphate Metabolism;Inositol Metabolism;Insulin Signaling;Metabolism of lipids;Inositol phosphate metabolism;3-phosphoinositide degradation;Metabolism;Inositol phosphate metabolism;Synthesis of PIPs at the early endosome membrane;Synthesis of PIPs at the plasma membrane;PI Metabolism;Phospholipid metabolism;Synthesis of IP2, IP, and Ins in the cytosol
(Consensus)
Recessive Scores
- pRec
- 0.113
Intolerance Scores
- loftool
- 0.270
- rvis_EVS
- -1.24
- rvis_percentile_EVS
- 5.46
Haploinsufficiency Scores
- pHI
- 0.271
- hipred
- Y
- hipred_score
- 0.724
- ghis
- 0.620
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.877
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Inpp4a
- Phenotype
- muscle phenotype; growth/size/body region phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- phosphatidylinositol biosynthetic process;signal transduction;dephosphorylation;phosphatidylinositol-3-phosphate biosynthetic process;inositol phosphate metabolic process
- Cellular component
- cytoplasm;cytosol
- Molecular function
- protein binding;phosphatidylinositol-3,4-bisphosphate 4-phosphatase activity;inositol-1,3,4-trisphosphate 4-phosphatase activity;phosphatidylinositol-4,5-bisphosphate 4-phosphatase activity;inositol-3,4-bisphosphate 4-phosphatase activity